Sacubitril/Valsartan Misses in HF, Preserved EF: PARAGON-HF Sacubitril/Valsartan Misses in HF, Preserved EF: PARAGON-HF
In the trial pitting Entresto against valsartan, the Novartis drug ' s effect on a composite primary end point fell short of significance in cursory top-line results announced by the company.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - July 30, 2019 Category: Cardiology Tags: Cardiology News Source Type: news
American Health Packaging Issues Voluntary Nationwide Recall of Valsartan Tablets Due to the Detection of NDEA (N-Nitrosodiethylamine) Impurity
Valsartan Tablets USP (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - July 26, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Drug for hereditary ovarian cancer approved
NICE grants faster access to life-extending drug olaparib Related items fromOnMedica NICE rejects breast cancer drug for NHS funding HPV programme linked to dramatic fall in cervical disease Withdrawn valsartan meds not linked to short-term cancer risk NHS prescription charge to rise to £9 Experts disappointed at NICE decision on ovarian cancer drug (Source: OnMedica Latest News)
Source: OnMedica Latest News - July 25, 2019 Category: UK Health Source Type: news
Critical heart drug too pricey for some Medicare patients
(University of Hawaii at Manoa) An effective drug to treat chronic heart failure may cost too much for senior citizens with a standard Medicare Part D drug plan, said a study co-authored by a John A. Burns School of Medicine researcher at the University of Hawaii at Manoa. The therapy is a combination of sacubitril/valsartan called Entresto ® . Researchers found that, even with insurance, the cost to Medicare patients may be more than $1,600 a year. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 22, 2019 Category: International Medicine & Public Health Source Type: news
Pharmacy flags another valsartan impurity, argues FDA standards are too high
Online pharmacy Valisure reported that it found a new carcinogenic impurity in some lots of blood pressure medicine valsartan, but the amount is still well below levels the FDA deemed potentially harmful. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - June 20, 2019 Category: Pharmaceuticals Source Type: news
Pharmacy Tests Turn Up Another Cancer-Causing Compound In Heart Drugs
(CNN) — Tests by an online pharmacy turned up another cancer-causing compound in heart medications, and these drugs haven’t been recalled.
Drugs containing valsaratan, losartan and irbesartan made by a variety of companies in a variety of countries have been taken off pharmacy shelves since July, when tests turned up chemicals in them that are considered carcinogens. The recalls of these angiotensin II receptor blockers or ARBs continue to expand. The US Food and Drug Administration keeps a regularly updated list of the drugs that have been recalled.
In this case, it’s not a recall. Instead, Valisure, an ...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - June 19, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News CNN Valsartan Source Type: news
Another cancer-causing chemical found in blood-pressure pills
Online pharmacy tells FDA it found carcinogenic solvent in valsartan heart drugs made by companies including Novartis (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - June 18, 2019 Category: Consumer Health News Source Type: news
Online pharmacy flags possible new impurity in blood pressure drug
Online pharmacy Valisure reported that it found a new cancer-causing impurity in some versions of widely prescribed blood pressure medicine valsartan, but U.S. regulators said on Tuesday that the amount in the drugs was well below levels deemed to be potentially harmful. (Source: Reuters: Health)
Source: Reuters: Health - June 18, 2019 Category: Consumer Health News Tags: healthNews Source Type: news
Antibiotic use linked to increased risk of heart attack and stroke in women
Risk is greatest for older women who take antibiotics for more than two months Related items fromOnMedica Withdrawn valsartan meds not linked to short-term cancer risk Cardio risk raised in people using long-acting bronchodilators Recurrent stroke more likely at very low BP Rising use of antithrombotics linked to subdural haematoma Adding insulin to metformin linked to higher mortality (Source: OnMedica Latest News)
Source: OnMedica Latest News - May 27, 2019 Category: UK Health Source Type: news
Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Valsartan / Amlodipine / HCTZ Tablets
Torrent Pharmaceuticals Limited is voluntarily recalling 14 lots of Valsartan/Amlodipine/HCTZ tablets to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Zhejiang Huahai Pharmaceuticals. The impurity detected in the API is N-nitrosodimethylamine (NDMA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) classification. (Source: FDA Center for Drug...
Source: FDA Center for Drug Evaluation and Research - What's New - May 24, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Valsartan Tablets, USP, 40mg, 80mg, 160mg and 320mg Due to The Detection of Trace Amounts of N-Nitrosodimethylamine (NDMA) Impurity, Found in an Active Pharmaceutical Ingredient (API)
As a precautionary measure, Camber Pharmaceuticals, Inc. is voluntarily recalling all unexpired lots of Valsartan Tablets, USP, 40mg, 80mg, 160mg and 320mg to the hospital, retail and consumer level. This recall of multiple batches of Valsartan Tablets was prompted due to the detection of trace amounts of N-Nitrosodimethylamine (NDMA), a possible process impurity or contaminant in an active pharmaceutical ingredient, manufactured by Hetero Labs Limited, Unit – I (API manufacturer). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 24, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Prinston Pharmaceutical Inc Issues Voluntary Nationwide Recall of Valsartan and Valsartan HCTZ Tablets Due to Detection of a Trace Amount of Unexpected Impurity, N-Nitrosodimethylamine (NDMA) in The Products
Prinston Pharmaceutical Inc. dba Solco Healthcare LLC. is recalling all lots of Valsartan Tablets, 40 mg, 80mg, 160mg, and 320mg; and Valsartan-Hydrochlorothiazide Tablets, 80mg/12.5mg, 160mg/12.5mg, 160mg/25mg, 320mg/12.5mg, and 320mg/25mg to the retail level. This product recall is due to the detection of a trace amount of an unexpected impurity, N-nitrosodimethylamine (NDMA), made by the manufacturer – Zhejiang Huahai Pharmaceutical Co. Ltd. -- that is used in the manufacture of the subject product lots. This impurity has been classified as a probable human carcinogen as per International Agency for Research on Cance...
Source: FDA Center for Drug Evaluation and Research - What's New - May 23, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Mylan Expands Its Voluntary Nationwide Recall of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, to all Lots Within Expiry Due to The Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in the Active Pharmaceuti
Mylan N.V. (NASDAQ: MYL) today announced that its U.S. based Mylan Pharmaceuticals business is expanding its consumer-level voluntary nationwide recall to include all lots of Valsartan-containing products within expiry. The 104 additional lots include 26 lots of Amlodipine and Valsartan Tablets, USP (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 21, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news
AurobindoPharma USA, Inc. Initiates a Voluntary Nationwide Consumer Level Recall Expansion of 38 Lots of Amlodipine Valsartan Tablets USP and Valsartan Tablets, USP due to the detection of NDEA (N-Nitrosodiethylamine) Impurity.
AurobindoPharma USA, Inc. is conducting a voluntary recall expansion of 38 lots of Valsartan and Amlodipine and Valsartan tablets to the consumer level due to the detection of trace amounts of an unexpected impurity found in the finished drug producAurobindoPharma USA, Inc. is conducting a voluntary (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 21, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news
How Some Generic Drugs Could Do More Harm Than Good
For the 16 years that Dr. Brian Westerberg, a Canadian surgeon, worked volunteer missions at the Mulago National Referral Hospital in Kampala, Uganda, scarcity was the norm. The patients usually exceeded the 1,500 allotted beds. Running water was once cut off when the debt-ridden hospital was unable to pay its bills. On some of his early trips, Westerberg even brought over drugs from Canada in order to treat patients. But as low-cost generics made in India and China became widely available through Uganda’s government and international aid agencies in the early 2000s, it seemed at first like the supply issue had been ...
Source: TIME: Health - May 17, 2019 Category: Consumer Health News Authors: Katherine Eban Tags: Uncategorized generic drugs medication medicine Source Type: news
